Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy
R. J. Kishton, S. J. Patel, S. K. Vodnala, A. K. Decker, Y. Patel, M. Sukumar, T. N. Yamamoto, Z. Yu, M. Ji, A. N. Henning, D. Gurusamy, D. C. Palmer, W. Lo, A. Pasetto, P. Malekzadeh, , N. P. Restifo
This study identifies genes that tumor cells use to resist T cell killing and shows that inhibiting BIRC2, ITGAV, or DNPEP enhances T cell-mediated tumor destruction.
bioRxiv · Nov 18, 2019 · PreprintImmunology